Published in final edited form as:

Curr Opin Pharmacol. 2014 June ; 0: 142–147. doi:10.1016/j.coph.2014.03.007.

Role for β -arrestin in mediating paradoxical β_2 AR and PAR₂ signaling in asthma

Julia K. L. Walker^{1,a} and Katherine A. DeFea^b

^aDuke University School of Nursing, Duke University Medical Center, Durham, NC 27710

^bDivision of Biomedical Sciences, University of California, Riverside, CA 92521

Abstract

G protein-coupled receptors (GPCRs) utilize (at least) two signal transduction pathways to elicit cellular responses including the classic G protein-dependent, and the more recently discovered β -arrestin-dependent, signaling pathways. In human and murine models of asthma, agonist-activation of β_2 -adrenergic receptor (β_2 AR) or Protease-activated-receptor-2 (PAR₂) results in relief from bronchospasm via airway smooth muscle relaxation. However, chronic activation of these receptors, leads to pro-inflammatory responses. One plausible explanation underlying the paradoxical effects of β_2 AR and PAR₂ agonism in asthma is that the beneficial and harmful effects are associated with distinct signaling pathways. Specifically, G protein-dependent signaling mediates relaxation of airway smooth muscle, whereas β -arrestin-dependent signaling promotes inflammation. This review explores the evidence supporting the hypothesis that β -arrestin-dependent signaling downstream of β_2 AR and PAR₂ is detrimental in asthma and examines the therapeutic opportunities for selectively targeting this pathway.

INTRODUCTION

Asthma is a chronic inflammatory disease characterized by airway inflammation, hyperresponsiveness and remodeling [1]. Airway hyperresponsiveness (AHR), a measure of bronchoconstrictor responsiveness, is associated with debilitating asthma signs and symptoms such as coughing, wheezing and shortness of breath. Beta-2-adrenergic receptor (β_2 -AR) agonist (β -agonist) administration is the mainstay therapy during bronchospastic episodes, providing significant relief to asthmatics [2]. However, chronic β -agonist therapy has also been associated with loss of asthma control, worsening of disease and increased morbidity and mortality (reviewed in [3]). Activation of Protease-activated receptor-2 (PAR₂), which promotes bronchorelaxation, has also been explored as a treatment for asthma. However, similar to the β_2 -adrenergic receptor (β_2 AR) paradox, murine studies have

© 2014 Elsevier Ltd. All rights reserved.

¹To whom correspondence should be addressed: Phone: 919-668-3252; walke082@mc.duke.edu.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

shown that PAR₂ activation can play diametrically opposed roles in allergic asthma providing both potent bronchorelaxation and increased inflammation [4]. Activation of dual independent signaling pathways by agonist binding to a single receptor may underlie these respective paradoxical effects. It is well known that signal transduction at the β_2 AR and PAR₂ (as well as a multitude of other GPCRs) occurs through classic G-protein-dependent signaling, as well as via the more recently described β -arrestin-dependent signaling pathway (Fig. 1) [5,6]. Interestingly, the two pathways are also temporally separable, with β -arrestin signaling sometimes occurring earlier than the G-protein signaling pathway [7], and other times exhibiting a delayed and/or more prolonged signal [8]. Consistent with these distinct signaling pathway characteristics, we and others have shown that β_2 AR and PAR₂ mediate bronchorelaxation through G protein-dependent signaling [4,9,10] and have accumulated evidence suggesting that β -arrestin-dependent signaling downstream of these receptors leads to a pro-inflammatory effect (Fig. 1) [4,11,12]. Because bronchorelaxation and inflammation are mediated via two independent signaling pathways, there is therapeutic potential in developing “biased” or “pathway-specific” ligands that preferentially activate or inhibit one signaling pathway over the other. Substantial murine and initial human data suggest that preferential activation of G-dependent, and inhibition of β -arrestin-dependent, signaling downstream of β_2 AR or PAR₂ receptors would promote desirable effects for asthmatics such as bronchodilation while reducing associated pro-inflammatory effects (reviewed in [3]). This review examines how the dual signaling pathways activated by ligand binding at the β_2 AR and PAR₂ give rise to both beneficial and detrimental effects in asthma and highlights β -arrestin-dependent signaling as the link underlying the parallels between the two.

β -arrestins

β -arrestins are adaptor proteins that are recruited to GPCRs to promote receptor desensitization and internalization, but they can also promote G-protein-independent signals, leading to a diverse array of physiological responses [5,6]. The role for β -arrestins in G protein-dependent signal termination occurs on several levels. The first characterized role for β -arrestins was the uncoupling of GPCRs from their cognate heterotrimeric G α subunit, leading to a decrease in the responsiveness of the receptor to further agonist stimulation. β -arrestins can also link receptors to clathrin-coated pits, facilitating their internalization. Finally, ubiquitination, and thus, degradation of internalized receptors is facilitated by β -arrestins. In this fashion, β -arrestins are thought to “arrest” the initial G-protein-triggered signal [13]. Over the last decade, a more extensive role for β -arrestins in GPCR signaling has become appreciated. β -arrestins can serve as scaffolds for signaling complexes that then promote G-protein-independent signals. Most of these signals are positive, in that they facilitate activation of the proteins they scaffold, but there are also examples of β -arrestin-dependent inhibition of the enzymatic activity of kinases and GTPases [7,14,15]. A common result of β -arrestin-dependent signaling is cell migration and actin reorganization, as well as transcription of specific genes not targeted by the G-protein pathway [13,16–18]. In some cases, these targets of β -arrestin-dependent inhibition are downstream of G-protein signaling pathways, providing yet another mechanism by which β -arrestins can turn off the G-protein signal. Both the desensitization and signaling roles for β -arrestins come into play in

physiological and pathological situations such as regulation of airway responsiveness and airway inflammation. While loss of β -arrestin-induced desensitization can result in uncontrolled G-protein signaling events, which can be pathological, other G-protein signaling events are protective and in the absence of β -arrestins, these protective pathways are enhanced. Furthermore, β -arrestins can promote inflammatory signals; thus in the absence of β -arrestin signaling downstream of a number of GPCRs, inflammation is abated [4,12,19]. This review focuses on two such receptors: β_2 AR and PAR₂, highlighting recent studies that demonstrate the potential therapeutic advantage of developing biased agonists or antagonists that target these receptors.

β_2 AR and PAR₂ signaling in asthma

Dual roles for β -arrestin and G protein signaling in mediating β_2 AR effects in asthma

β_2 ARs are ubiquitously expressed and modulate a wide range of cellular responses when activated by epinephrine, their only endogenous ligand [20]. In the airway smooth muscle (ASM) agonist-activated β_2 ARs couple to G α_s resulting in stimulation of membrane bound adenylyl cyclase, cyclic adenosine monophosphate (cAMP) generation and activation of the cAMP-dependent protein kinase (PKA), which mediates relaxation through phosphorylation of cross-bridge cycling regulatory proteins. In addition to the G α_s /cAMP second messenger system, β_2 ARs also mediate cellular responses via G α_i – induced generation of cGMP and Ca²⁺; however, cAMP/PKA is the predominant mechanism underlying ASM relaxation (for a more complete review see [21] and Pera and Penn this issue). Through activation of β_2 AR coupling to G α_s , beta-agonists oppose airway smooth muscle (ASM) constriction and inhibit the release of pro-contractile agents, chiefly vagally-released acetylcholine (reviewed in [21,22]). We have shown using multiple methods (*in vitro*, *ex vivo* and *in vivo*) that β -arrestin-2 constrains β_2 AR-mediated G protein-dependent ASM relaxation [9] making β -arrestin-2 inhibition an attractive therapeutic strategy in asthma irrespective of its pro-inflammatory role.

Shenoy et al. were the first to show that β_2 ARs can utilize a G-protein-independent, β -arrestin-dependent signaling pathway to exert physiological effects [23]. Since then, several pieces of evidence, when taken together, suggest that β_2 AR-mediated β -arrestin-dependent signaling is pro-inflammatory in asthma. Firstly, β -arrestins have been implicated as regulators of inflammation in a variety of diseases including asthma, sepsis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis [24,25]. Lung β -arrestin expression is up-regulated in murine models of asthma [10] and is similarly dynamically regulated in other inflammatory diseases [24]. Results from multiple murine studies have shown that the asthma phenotype is strikingly diminished in β -arrestin-2^{-/-} mice irrespective of the method of induction of allergic airway disease [4,12,19]. Although development of the asthma phenotype is likely mediated by multiple GPCRs that signal through the β -arrestin-dependent pathway, β_2 ARs are distinguished as being extremely important. Results from murine studies have shown that the asthma phenotype is significantly suppressed when either β_2 AR expression or epinephrine synthesis is genetically abrogated [26,27]. Furthermore, blockade of β_2 AR with select β_2 AR antagonists (nadolol) can significantly diminish asthma severity in murine models [26,28] and reduce airway

sensitivity to methacholine in human trials [29]. Finally, chronic dosing with β -agonists can restore the asthma phenotype in mice that lack epinephrine or exacerbate it in mice that are replete with epinephrine [10,27,30] strongly suggesting that the deleterious effects associated with chronic β_2 AR agonism in asthma result from β -arrestin-2-dependent signaling.

Like β_2 ARs, β -arrestin proteins are also widely expressed. Thus, presently it is unknown in which cell type(s) β_2 AR-mediated β -arrestin-dependent signaling contributes to the development of asthma. Recent evidence points to airway epithelial cells as playing a key role [31]. Airway epithelial expression of membrane-bound β_2 AR and cytosolic β -arrestin-2 is significantly elevated relative to that in ASM cells [9,10] or T lymphocytes (unpublished data), two additional cell types that also figure prominently in asthma pathogenesis, and the magnitude of impairment of the mucin phenotype in β_2 AR^{-/-} mice is noticeably greater than that of the inflammatory cell or AHR phenotypes [11]. However, data from β -arrestin-2^{-/-} bone marrow transplant chimeric mice suggest that β arr-mediated signal transduction in hematopoietic cells, in addition to that in lung structural cells, is required for full development of the asthma phenotype [19]. Consistent with this notion, both PAR₂- and C-C chemokine receptor 4 (CCR4)-mediated inflammatory cell chemotaxis is β -arrestin-dependent [4,12] in murine asthma models.

Dual roles for β -arrestin and G-protein signaling in mediating PAR₂ effects in asthma

PAR₂ is widely expressed on inflammatory cells, airway epithelium, smooth muscle and vascular endothelium, where it is activated by serine proteases that cleave the extracellular N-terminus to unveil a tethered ligand (human: SLIGKV/mouse: SLIGRL)[32,33]. This tethered ligand then binds to and activates the receptor, triggering downstream signaling events. Recently, high-affinity and stable agonists, such as 2-furoyl-LIGRL-O (aka 2fAP), have been developed and used both *in vivo* and *in vitro* to activate PAR₂ [34–36]. Although PAR₂ has been implicated in a number of inflammatory disorders, and has been heavily investigated as a putative therapeutic target for asthma, the nature of its involvement remains highly controversial. In favor of a protective role for PAR₂ in the airway, PAR₂^{-/-} mice demonstrate heightened bronchial smooth muscle cell contraction and airway constriction, and administration of a PAR₂ peptide agonist promotes smooth muscle relaxation in isolated bronchioles and abrogates LPS-mediated inflammation [32,37,38]. In contrast, in an OVA-induced model of airway inflammation, cytokine production and infiltration of leukocytes into the bronchioles is impaired in PAR₂^{-/-} mice, suggesting a pro-inflammatory role for PAR₂ [39–42], and intranasal administration of SLIGRL or 2fAP exacerbates these effects [4,43,44].

Recent studies have provided a plausible answer to this conundrum of the PAR₂ role in asthma. First, cytoskeletal reorganization and chemotaxis, which are the main cellular processes underlying the pro-inflammatory effects of PAR₂, do not require G α_q /Ca²⁺ signaling, but rather utilize β -arrestins [7,14,45,46]. β -arrestins can signal to various actin assembly pathways to promote chemotaxis, but a major player in PAR₂/ β -arrestin signaling is the actin filament severing protein, cofilin [7,47]. Conversely, other studies have demonstrated that PAR₂-induced smooth muscle relaxation, which initiates the protective

effects in the airway, is mediated by prostaglandin E₂ (PGE₂), derived from epithelial cells. PGE₂ production requires Gαq-induced mobilization of intracellular Ca²⁺, activation of PI3K and phosphorylation of Akt (which leads to release of PGE₂), and nuclear ERK1/2 activation (which leads to expression of cyclooxygenase-1 and -2) [37,48]. Solidifying the importance of the PAR₂/β-arrestin signaling axis to inflammation in a modified mouse OVA-induced asthma model are the observations that PAR₂-induced recruitment of leukocytes to the airways, mucus production and cytokine release are abolished in β-arrestin-2^{-/-} mice, while PGE₂ release and smooth muscle relaxation remain intact [4]. These studies suggest that two different signaling pathways may account for the contrasting effects of PAR₂: β-arrestin-dependent leukocyte chemotaxis and Gαq-dependent PGE₂ production.

Just as β₂ARs are ubiquitously expressed, so too is PAR₂, being found in the airway epithelium as well as the invading leukocytes (neutrophils, eosinophils, lymphocytes and macrophages) [37,49–51]. The protective effects of PAR₂ have been shown to be epithelium-dependent, as PGE₂ production and smooth muscle relaxation in bronchiolar rings in response to PAR₂ agonists is abolished when the epithelial cells are removed [48,51]. PAR₂-induced inflammation in mice is significantly reduced when wild type mice are transplanted with PAR₂^{-/-} bone marrow, suggesting a crucial role for PAR₂ expressed on the infiltrating leukocytes [4]. However, PAR₂^{-/-} mice transplanted with wild type bone marrow also showed reduced leukocyte infiltration, pointing to a role of epithelial PAR₂ in the progression of inflammation as well as the protective PGE₂ release. Together these data suggest that β-arrestins expressed within the structural and epithelial cells of the lungs, as well as invading leukocytes, contribute to the inflammatory responses during asthma.

Therapeutic Opportunities

Therapeutic targeting of GPCRs has, until very recently, been focused entirely on modulation of responses thought to be mediated by G protein-dependent signaling pathways. With the discovery that GPCRs also utilize β-arrestin-dependent signaling to cause physiological (and pathophysiological) effects, comes the opportunity to therapeutically regulate a second signaling pathway. Specifically, the now established concept of *dual independent GPCR signaling pathways* allows us to consider the possibility that one signaling pathway can be selectively manipulated to promote events that are therapeutic and avoid, or even inhibit, those that are harmful. For example, the superior clinical efficacy of carvedilol over other β-blockers, which inhibit classic G protein adrenoceptor signaling, in treating heart failure is attributed to carvedilol's activation of the β-arrestin-dependent signaling pathway [52]. Whereas β-arrestin-dependent signaling is beneficial in heart failure, it appears deleterious in several other diseases (cancer, atherosclerosis, chronic inflammation) including asthma. Substantial murine, and initial human, data suggest that asthma treatment would be significantly improved by preferential activation of β₂AR- and PAR₂-mediated G protein-dependent bronchodilation and/or inhibition of β-arrestin-dependent pro-inflammatory signaling.

Appreciation for the impact of β-arrestin-dependent signaling on drug discovery is rapidly emerging in the quest for biased ligands, allosteric receptor modulators and β-arrestin

inhibitor compounds. Recently developed cell based assays demonstrate that endogenous GPCR ligands are unbiased, in that they activate both the G protein- and β -arrestin-dependent signaling pathways at functionally relevant levels (Fig. 2a). Using these assays, β_2 AR or PAR₂ ligands that favor G signaling over β -arrestin signaling could be found, or designed, and used to treat asthma (Fig. 2b). As an alternative approach, the signaling effects of an unbiased ligand could be shifted to favor Gs-dependent signaling over β -arrestin-dependent signaling by addition of a second drug that, through allosteric modulation, moves the receptor into a biased signaling conformation (Fig. 2c) (see Thanawala this issue). Along the same lines, an unbiased ligand could give rise to G protein-biased signaling if β -arrestin was pharmacologically prevented from participating in signal transduction (Fig. 2d). Yet another angle by which unbiased ligand-induced G protein-dependent signaling might be favored over that mediated by β -arrestin is to develop a drug that inhibits β -arrestin-mediated constraint of G protein-dependent bronchorelaxation (Fig. 2e). Such a drug may allow a normal bronchodilation effect to be generated by a much lower dose of β -agonist/PAR₂-agonist which in turn would only weakly activate the pro-inflammatory β -arrestin-dependent signaling pathway.

Concluding remarks

Unbiased agonists acting at either β_2 AR or PAR₂ elicit paradoxical responses in asthma. Evidence suggests that ligand-induced protective bronchodilation and deleterious pro-inflammation are mediated through separate G protein- and β -arrestin-dependent signaling pathways, respectively. Selective promotion of the protective signaling pathway or inhibition of the inflammatory one, will lead to therapeutic advances in the treatment of asthma.

Acknowledgments

This work was supported by National Institutes of Health Grants 1R21HL092388 (to K.A.D.) and R01HL084123 and R01HL093103 (to J.K.L.W.).

References and recommended readings

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
 - of outstanding interest
1. Walker JKL, Kraft M, Fisher JT. Assessment of murine lung mechanics outcome measures: alignment with those made in asthmatics. *Frontiers in Physiology*. 2013; 3
 2. (NAEPP) NAEaPP: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007. *Journal of Allergy and Clinical Immunology*. 2007; 120:S94–S138. [PubMed: 17983880]
 3. Walker JKL, Penn RB, Hanania NA, Dickey BF, Bond RA. New perspectives regarding β_2 -adrenoceptor ligands in the treatment of asthma. *British Journal of Pharmacology*. 2011; 163:18–28. [PubMed: 21175591]
 - 4••. Nichols HL, Saffeddine M, Theriot BS, Hegde A, Polley D, El-Mays T, Vliagoftis H, Hollenberg MD, Wilson EH, Walker JKL, et al. β -Arrestin-2 mediates the proinflammatory effects of

proteinase-activated receptor-2 in the airway. *Proceedings of the National Academy of Sciences*. 2012; 109:16660–16665. This study demonstrates that unbiased PAR₂ ligands mediate protective bronchorelaxation and deleterious inflammation via the G protein-dependent and β -arrestin-dependent signaling pathways, respectively, in an antigen-driven murine asthma model.

5. Lefkowitz RJ, Whalen EJ. [beta]-arrestins: traffic cops of cell signaling. *Curr Opin Cell Biol*. 2004; 16:162–168. [PubMed: 15196559]
6. Lefkowitz RJ, Rajagopal K, Whalen EJ. New Roles for β -Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors. *Molecular Cell*. 2006; 24
7. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. *J Biol Chem*. 2007; 282:20634–20646. [PubMed: 17500066]
8. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. *J Biol Chem*. 2004; 279:35518–35525. [PubMed: 15205453]
9. Deshpande DA, Theriot BS, Penn RB, Walker JK. Beta-arrestins specifically constrain beta₂-adrenergic receptor signaling and function in airway smooth muscle. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2008; 22:2134–2141. This study shows that β -arrestin significantly constrains β_2 AR-mediated bronchorelaxation by interrupting G protein-dependent signaling, making β -arrestin an attractive therapeutic target for the treatment of asthma. [PubMed: 18337459]
10. Lin R, Degan S, Theriot BS, Fischer BM, Strachan RT, Liang J, Pierce RA, Sunday ME, Noble PW, Kraft M, et al. Chronic treatment in vivo with β -adrenoceptor agonists induces dysfunction of airway β_2 -adrenoceptors and exacerbates lung inflammation in mice. *British Journal of Pharmacology*. 2012; 165:2365–2377. [PubMed: 22013997]
11. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, Giles H, Shardonofsky FR, Bond RA. Effects of acute and chronic administration of β -adrenoceptor ligands on airway function in a murine model of asthma. *Proc Natl Acad Sci U S A*. 2004; 101:4948–4953. [PubMed: 15069206]
12. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, Lefkowitz RJ. Beta-arrestin-2 regulates the development of allergic asthma. *The Journal of clinical investigation*. 2003; 112:566–574. This study shows that β -arrestin-2 expression is crucial to the development of inflammation and airway hyperresponsiveness in an antigen-driven murine asthma model. [PubMed: 12925697]
13. Shenoy SK, Lefkowitz RJ. Seven-transmembrane receptor signaling through beta-arrestin. *Science's STKE: signal transduction knowledge environment*. 2005; 2005:cm10.
14. Wang P, Jiang Y, Wang Y, Shyy JY, DeFea KA. Beta-arrestin inhibits CAMKK β -dependent AMPK activation downstream of protease-activated-receptor-2. *BMC Biochem*. 2010; 11:36. [PubMed: 20858278]
15. Wang P, Kumar P, Wang C, DeFea KA. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 α and β by protease-activated receptor 2 and beta-arrestins. *Biochem J*. 2007; 408:221–230. [PubMed: 17680774]
16. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. *Annual Review of Physiology*. 2007; 69:483–510.
17. DeFea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. *Br J Pharmacol*. 2008; 153 (Suppl 1):S298–309. [PubMed: 18037927]
18. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. *Pharmacological reviews*. 2010; 62:305–330. [PubMed: 20427692]
19. Hollingsworth JW, Theriot BS, Li Z, Lawson BL, Sunday M, Schwartz DA, Walker JK. Both hematopoietic-derived and non-hematopoietic-derived {beta}-arrestin-2 regulates murine allergic airway disease. *American journal of respiratory cell and molecular biology*. 2010; 43:269–275. [PubMed: 19805483]
20. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. *Nature*. 1967; 214:597–598. [PubMed: 6036174]

21. Penn, R.; Bond, R.; Walker, J.L. GPCRs and Arrestins in Airways: Implications for Asthma. In: Gurevich, VV., editor. *Arrestins - Pharmacology and Therapeutic Potential*. Vol. 219. Springer; Berlin Heidelberg: 2014. p. 387-403. *Handbook of Experimental Pharmacology*
22. Billington C, Penn R. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. *Respir Res*. 2003; 4:2. [PubMed: 12648290]
23. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, Lefkowitz RJ. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. *The Journal of biological chemistry*. 2006; 281:1261–1273. [PubMed: 16280323]
24. Fan H. β -Arrestins 1 and 2 are critical regulators of inflammation. *Innate Immunity*. 2013
25. Vroon A, Heijnen CJ, Kavelaars A. GRKs and arrestins: regulators of migration and inflammation. *Journal of Leukocyte Biology*. 2006; 80:1214–1221. [PubMed: 16943386]
26. Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, Knoll BJ, Dickey BF, Bond RA. β 2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. *Proc Natl Acad Sci U S A*. 2009; 106:2435–2440. This study shows that β 2-adrenoceptor null mice are resistant to developing airway hyperresponsiveness, mucous metaplasia, and inflammatory cells in bronchoalveolar lavage fluid, compared to wild type mice in an antigen-driven murine asthma model. [PubMed: 19171883]
27. Thanawala VJ, Forkuo GS, Al-Sawalha N, Azzegagh Z, Nguyen LP, Eriksen JL, Tuvim MJ, Lowder TW, Dickey BF, Knoll BJ, et al. β 2-adrenoceptor Agonists are Required for Development of the Asthma Phenotype in a Murine Model. *American Journal of Respiratory Cell and Molecular Biology*. 2013
28. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. *American journal of respiratory cell and molecular biology*. 2008; 38:256–262. [PubMed: 18096872]
29. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, et al. The safety and effects of the β -blocker, nadolol, in mild asthma: an open-label pilot study. *Pulm Pharmacol Therapeut*. 2008; 21:134–141.
30. Riesenfeld E, Sullivan M, Thompson-Figueroa J, Haverkamp H, Lundblad L, Bates J, Irvin C. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. *Respir Res*. 2010; 11:22. [PubMed: 20181256]
31. Dickey BF, Walker JK, Hanania NA, Bond RA. beta-Adrenoceptor inverse agonists in asthma. *Current opinion in pharmacology*. 2010; 10:254–259. [PubMed: 20399707]
32. Cocks TM, Moffatt JD. Protease-activated receptor-2 (PAR2) in the airways. *Pulm Pharmacol Ther*. 2001; 14:183–191. [PubMed: 11448145]
33. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. *Nature reviews Drug discovery*. 2012; 11:69–86.
34. McGuire JJ, Saifeddine M, Trigg CR, Sun K, Hollenberg MD. 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. *J Pharmacol Exp Ther*. 2004; 309:1124–1131. [PubMed: 14976230]
35. Boitano S, Flynn AN, Schulz SM, Hoffman J, Price TJ, Vagner J. Potent agonists of the protease activated receptor 2 (PAR2). *Journal of medicinal chemistry*. 2011; 54:1308–1313. [PubMed: 21294569]
36. Flynn AN, Hoffman J, Tillu DV, Sherwood CL, Zhang Z, Patek R, Asiedu MN, Vagner J, Price TJ, Boitano S. Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2013; 27:1498–1510. [PubMed: 23292071]
37. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD. A protective role for protease-activated receptors in the airways. *Nature*. 1999; 398:156–160. [PubMed: 10086357]
38. Moffatt JD, Jeffrey KL, Cocks TM. Protease-Activated Receptor-2 Activating Peptide SLIGRL Inhibits Bacterial Lipopolysaccharide-Induced Recruitment of Polymorphonuclear Leukocytes into the Airways of Mice. *Am J Respir Cell Mol Biol*. 2002; 26:680–684. [PubMed: 12034566]

39. Gatti R, Andre E, Amadesi S, Dinh TQ, Fischer A, Bunnett NW, Harrison S, Geppetti P, Trevisani M. Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs. *J Appl Physiol*. 2006; 101:506–511. [PubMed: 16627674]
40. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. *J Immunol*. 2002; 169:5315–5321. [PubMed: 12391252]
41. Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, Caughey G, Tognetto M, Cavallero G, Mapp C, Geppetti P, et al. Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. *Am J Respir Crit Care Med*. 2001; 164:1276–1281. [PubMed: 11673222]
42. Takizawa T, Tamiya M, Hara T, Matsumoto J, Saito N, Kanke T, Kawagoe J, Hattori Y. Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice. *J Pharmacol Sci*. 2005; 98:99–102. [PubMed: 15879675]
43. Ebeling C, Lam T, Gordon JR, Hollenberg MD, Vliagoftis H. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. *J Immunol*. 2007; 179:2910–2917. [PubMed: 17709505]
44. Ebeling C, Forsythe P, Ng J, Gordon JR, Hollenberg M, Vliagoftis H. Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. *J Allergy Clin Immunol*. 2005; 115:623–630. [PubMed: 15753914]
45. Ge L, Ly Y, Hollenberg M, DeFea K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. *J Biol Chem*. 2003; 278:34418–34426. [PubMed: 12821670]
46. Wang P, DeFea KA. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and G α q-dependent activation of phosphatidylinositol 3-kinase. *Biochemistry*. 2006; 45:9374–9385. [PubMed: 16878972]
47. DeFea KA. Stop that cell! Beta-arrestin-dependent chemotaxis: a tale of localized actin assembly and receptor desensitization. *Annu Rev Physiol*. 2007; 69:535–560. [PubMed: 17002593]
48. Nagataki M, Moriyuki K, Sekiguchi F, Kawabata A. Evidence that PAR2-triggered prostaglandin E₂ (PGE₂) formation involves the ERK-cytosolic phospholipase A₂-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. *Cell Biochem Funct*. 2008; 26:279–282. [PubMed: 17708577]
49. Shpacovitch V, Feld M, Bunnett NW, Steinhoff M. Protease-activated receptors: novel PARTners in innate immunity. *Trends Immunol*. 2007; 28:541–550. [PubMed: 17977790]
50. Bunnett NW. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. *Semin Thromb Hemost*. 2006; 32 (Suppl 1):39–48. [PubMed: 16673265]
51. Kawabata A, Kubo S, Ishiki T, Kawao N, Sekiguchi F, Kuroda R, Hollenberg MD, Kanke T, Saito N. Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: signal transduction mechanisms and distinct agonist sensitivity. *J Pharmacol Exp Ther*. 2004; 311:402–410. [PubMed: 15199093]
52. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ. A unique mechanism of β -blocker action: Carvedilol stimulates β -arrestin signaling. *Proc Natl Acad Sci U S A*. 2007; 104:16657–16662. [PubMed: 17925438]

Highlights

1. β_2 AR or PAR₂ activation is both protective and pro-inflammatory in asthma
2. β_2 AR and PAR₂ G protein-dependent signaling is protective in asthma
3. β_2 AR and PAR₂ β -arrestin-dependent signaling is pro-inflammatory in asthma
4. Biased activation of PAR₂ and β_2 AR G protein signaling may improve asthma treatment.
5. Biased inhibition of PAR₂ and β_2 AR β -arrestin signaling may improve asthma treatment.

Figure 1. Dual signaling pathways and paradoxical response to bronchodilators

Activation of $\beta_2\text{AR}$ or PAR_2 leads to both β -arrestin-dependent and G protein-dependent signaling. Activation of the G protein-dependent pathway leads to bronchorelaxation whereas activation of the β -arrestin-2-dependent signaling pathway is pro-asthmatic. ($\beta_2\text{AR}$, beta-2-adrenergic receptor; PAR_2 , protease-activated-receptor-2; ASM, airway smooth muscle).

Figure 2. Impact of β -arrestin-dependent signaling on drug discovery for asthma treatment

a) Unbiased GPCR ligand functionally activates both the G protein- and β -arrestin-dependent signaling pathways leading to bronchorelaxation and inflammation, respectively; b) Biased ligand favors G signaling over β -arrestin signaling; c) Allosteric modulation of the receptor facilitates biased signaling even though the ligand is unbiased; d) Intracellular inhibition of β -arrestin-dependent signaling; e) Low dose unbiased agonist results in normal ASM relaxation due to intracellular inhibition of β -arrestin-mediated constraint of G protein signaling. UBL, unbiased ligand; BL, biased ligand; AM, allosteric modulator; GPCR, G protein-coupled receptor, ASM relax, airway smooth muscle relaxation; Pro-inflam, pro-inflammatory; β arr, β -arrestin.